Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up

Dara Christante, Su Ellen Johnson Pommier, Jennifer Garreau, Patrick Muller, Brett LaFleur, Rodney Pommier

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    Background: We previously reported that breast cancer patients who used hormone replacement therapy (HRT) had significantly lower stage tumors and higher survival than never-users. We present an update with longer follow-up, HRT use data, and in vitro research. Methods: Our database of 292 postmenopausal breast cancer patients was updated to include HRT type, duration, and disease status. In vitro effects of estrogen (E) and/or medroxyprogesterone (MPA) on breast cancer cell growth were measured. Results: Tumor prognostic factors were better and survival rates higher for both E and combination HRT users of any duration. Use greater than 10 years correlated with node-negative disease, mammographically detected tumors, and 100% survival. E supported minimal proliferation; MPA induced cell death; E+MPA results were similar to E alone. Conclusions: HRT users, regardless of type or duration of HRT use, continued to have higher survival rates. In vitro results supported the clinical finding that outcomes for users of E and E+MPA were similar.

    Original languageEnglish (US)
    Pages (from-to)505-511
    Number of pages7
    JournalAmerican Journal of Surgery
    Volume196
    Issue number4
    DOIs
    StatePublished - Oct 2008

    Fingerprint

    Hormone Replacement Therapy
    Breast Neoplasms
    Survival
    Survival Rate
    Medroxyprogesterone
    Neoplasms
    Estrogens
    Cell Death
    Databases
    Growth
    Research
    In Vitro Techniques

    Keywords

    • Breast cancer
    • Hormone replacement therapy
    • Medroxyprogesterone

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. / Christante, Dara; Pommier, Su Ellen Johnson; Garreau, Jennifer; Muller, Patrick; LaFleur, Brett; Pommier, Rodney.

    In: American Journal of Surgery, Vol. 196, No. 4, 10.2008, p. 505-511.

    Research output: Contribution to journalArticle

    @article{7f9ee839a7984156ba779eeba2d48dfd,
    title = "Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up",
    abstract = "Background: We previously reported that breast cancer patients who used hormone replacement therapy (HRT) had significantly lower stage tumors and higher survival than never-users. We present an update with longer follow-up, HRT use data, and in vitro research. Methods: Our database of 292 postmenopausal breast cancer patients was updated to include HRT type, duration, and disease status. In vitro effects of estrogen (E) and/or medroxyprogesterone (MPA) on breast cancer cell growth were measured. Results: Tumor prognostic factors were better and survival rates higher for both E and combination HRT users of any duration. Use greater than 10 years correlated with node-negative disease, mammographically detected tumors, and 100{\%} survival. E supported minimal proliferation; MPA induced cell death; E+MPA results were similar to E alone. Conclusions: HRT users, regardless of type or duration of HRT use, continued to have higher survival rates. In vitro results supported the clinical finding that outcomes for users of E and E+MPA were similar.",
    keywords = "Breast cancer, Hormone replacement therapy, Medroxyprogesterone",
    author = "Dara Christante and Pommier, {Su Ellen Johnson} and Jennifer Garreau and Patrick Muller and Brett LaFleur and Rodney Pommier",
    year = "2008",
    month = "10",
    doi = "10.1016/j.amjsurg.2008.06.023",
    language = "English (US)",
    volume = "196",
    pages = "505--511",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "4",

    }

    TY - JOUR

    T1 - Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up

    AU - Christante, Dara

    AU - Pommier, Su Ellen Johnson

    AU - Garreau, Jennifer

    AU - Muller, Patrick

    AU - LaFleur, Brett

    AU - Pommier, Rodney

    PY - 2008/10

    Y1 - 2008/10

    N2 - Background: We previously reported that breast cancer patients who used hormone replacement therapy (HRT) had significantly lower stage tumors and higher survival than never-users. We present an update with longer follow-up, HRT use data, and in vitro research. Methods: Our database of 292 postmenopausal breast cancer patients was updated to include HRT type, duration, and disease status. In vitro effects of estrogen (E) and/or medroxyprogesterone (MPA) on breast cancer cell growth were measured. Results: Tumor prognostic factors were better and survival rates higher for both E and combination HRT users of any duration. Use greater than 10 years correlated with node-negative disease, mammographically detected tumors, and 100% survival. E supported minimal proliferation; MPA induced cell death; E+MPA results were similar to E alone. Conclusions: HRT users, regardless of type or duration of HRT use, continued to have higher survival rates. In vitro results supported the clinical finding that outcomes for users of E and E+MPA were similar.

    AB - Background: We previously reported that breast cancer patients who used hormone replacement therapy (HRT) had significantly lower stage tumors and higher survival than never-users. We present an update with longer follow-up, HRT use data, and in vitro research. Methods: Our database of 292 postmenopausal breast cancer patients was updated to include HRT type, duration, and disease status. In vitro effects of estrogen (E) and/or medroxyprogesterone (MPA) on breast cancer cell growth were measured. Results: Tumor prognostic factors were better and survival rates higher for both E and combination HRT users of any duration. Use greater than 10 years correlated with node-negative disease, mammographically detected tumors, and 100% survival. E supported minimal proliferation; MPA induced cell death; E+MPA results were similar to E alone. Conclusions: HRT users, regardless of type or duration of HRT use, continued to have higher survival rates. In vitro results supported the clinical finding that outcomes for users of E and E+MPA were similar.

    KW - Breast cancer

    KW - Hormone replacement therapy

    KW - Medroxyprogesterone

    UR - http://www.scopus.com/inward/record.url?scp=52049092991&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=52049092991&partnerID=8YFLogxK

    U2 - 10.1016/j.amjsurg.2008.06.023

    DO - 10.1016/j.amjsurg.2008.06.023

    M3 - Article

    C2 - 18809052

    AN - SCOPUS:52049092991

    VL - 196

    SP - 505

    EP - 511

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 4

    ER -